(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 March 2006 (23.03.2006)

PCT

(10) International Publication Number
WO 2006/030220 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 37/06* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/GB2005/003562

(22) International Filing Date:
16 September 2005 (16.09.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/610,819 17 September 2004 (17.09.2004) US
11/105,512 8 April 2005 (08.04.2005) US

(71) Applicant *(for all designated States except US)*: **DOMANTIS LIMITED** [GB/GB]; 315 Cambridge Science Park, Cambridge CB4 0WG (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **GRANT, Steven** [GB/GB]; 315 Cambridge Science Park, Cambridge, Cambridgeshire CB4 0WG (GB). **LIU, Haiqun** [CN/GB]; 315 Cambridge Science Park, Cambridge, Cambridgeshire CB4 0WG (GB). **MOULDER, Kevin** [GB/GB]; 315 Cambridge Science Park, Cambridge, Cambridgeshire CB4 0WG (GB).


(74) Agent: **THOMAS, Philip**; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH,

[Continued on next page]

(54) Title: COMPOSITIONS MONOVALENT FOR CD40L BINDING AND METHODS OF USE



(57) Abstract: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of CD40L. In one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD40L, preferably without substantially agonizing CD40 and/or CD40L activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/CD40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.

WO 2006/030220 A1

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report*

(48) Date of publication of this corrected version:
19 October 2006

(15) Information about Correction:
see PCT Gazette No. 42/2006 of 19 October 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.